Status:
COMPLETED
Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors
Lead Sponsor:
Sanofi
Conditions:
Neoplasms, Malignant
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Primary Objective: \- To determine the maximum administered dose (MAD) and the maximum tolerated dose (MTD) of ombrabulin in combination with best tolerated dose of bevacizumab based on the incidence...
Detailed Description
The duration of the study for each patient will include an up to 28-day screening phase, 21-day study treatment cycles, an end of treatment visit with a follow-up period. Each patient will participate...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Histologically or cytologically proven solid malignant tumor at the first diagnosis with the exception of squamous non small cell lung cancer (NSCLC).
- Advanced neoplastic disease (i.e. metastatic or locally unresectable advanced disease)
- Presence of one measurable lesion at baseline in the MTD expanded cohort
- Exclusion criteria:
- ECOG (Eastern cooperativeOncology Group) performance status \> 1
- Concurrent treatment with any other anticancer therapy
- Pericardial effusion requiring intervention (drainage)
- History of brain metastasis, spinal cord compression or carcinomatous meningitis or new evidence of brain metastasis on screening Computed tomography (CT) or Magnetic resonance imaging (MRI) scan
- Diagnosis of squamous Non Squamous Cell Lung Cancer (NSCLC) or with mixed cell type with predominant squamocellular histology
- Hormone sensitive prostate cancer
- Abdominal Radiotherapy
- Major surgery within the last month of study enrollment or surgical wound not fully healed before study enrollment
- High cumulative doses of anthracycline
- Inadequate organ function
- Inadequate hematology function or poor bone marrow reserve
- Any of the following within 6 months prior to study enrollment: peptic ulcer disease, erosive oesophagitis or gastritis, infectious or inflammatory bowel disease and diverticulitis
- Any history or underlying cardiac condition that may increase the risks associated with the study participation or administration of the investigational products, or that may interfere with the interpretation of the results.
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Exclusion
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT01193595
Start Date
September 1 2010
End Date
October 1 2014
Last Update
December 3 2014
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational Site Number 250001
Villejuif, France, 94805
2
Investigational Site Number 380002
Milan, Italy, 20132
3
Investigational Site Number 380001
Milan, Italy, 20133
4
Investigational Site Number 826001
Sutton, United Kingdom, SM2 5PT